Trials of a COVID-19 vaccine seen as a strong contender among dozens being developed will resume after being halted due to a side effect in a UK patient.
The vaccine is being developed by Oxford University and pharmaceutical AstraZeneca.
The studies were paused earlier this week after a reported side effect with the vaccine. Oxford University will not disclose the nature of the patient’s illness citing confidentiality.
In a statement on Saturday, Oxford University said that it was “expected” that “some participants will become unwell” in large trials like this one.
The trials for this vaccine have moved into Phase 3 and have involved about 30, 000 participants from several countries. Phase 3 trials can last several years.